Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer

The Lancet

Volumn 343, Issue 8906, 1994, Pages 1122-1126

  Nakazato, Hiroaki ^f   Koike, Akihiko ^f   Saji, Shigetoyo ^f   Ogawa, Nobuya ^f   Sakamoto, Junichi ^f   Nakazato, H ^a   Koike, A ^b   Saji, S ^c   Ogawa, N ^d   Sakamoto, J ^e   Study Group of Immunochemotherapy with PSK for Gastric Cancer, ^f  

^a Yokoyama Gastrointestinal Hospital ^*  (United Kingdom)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Department of Gastroenterological Surgery Aichi Cancer Center ^*  (United Kingdom)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MITOMYCIN; POLYSACCHARIDE; PROTEIN BOUND CARBOHYDRATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; IMMUNOTHERAPY; JAPAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH CANCER; SURVIVAL;

EID: 0028273259     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(94)90233-X     Document Type: Article

References (25)

1. Epidemiology and pathology of gastric cancer
2. Cancer of the stomach in Japan
3. Postoperative adjuvant chemotherapy for gastric cancer. Carcinoma: analysis of data on 1805 patients followed for 5 years
4. Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection
5. Result of adjuvant immunochemotherapy on 8-year survival using Krestin and Futraful for gastric cancer patients who underwent radical gastrectomy: a randomized controlled trial by cooperative study group (in Japanese)
6. Experimental design of clinical trials
7. Evaluation of survival data and two new rank order statistics arising in its consideration
8. Production of antiserum against antitumour protein-bound polysaccharide preparation, PSK (Krestin) and its pharmacological application
9. A suppressive effect of PSK protein-bound polysaccharide preparation on tumor growth: a new effect of PSK on cell motility (in Japanese).
10. The therapeutic effects of an immunopotentiator PS-K on 3-methylcholanthrene- induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites
11. Combined therapeutic effects of conventional agents and an immunomodulator, PSK, on rat prostatic adenocarcinoma
12. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells
13. Antitumor effect of PSK at a distant site: inductions of interleukin-8-like factor and macrophage chemotactic factor in murine tumor
14. Indication of immunochemotherapy using PSK for gastric cancer from the standpoint of host factors and studies of antitumour effects and PSK mechanism (in Japanese)
15. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer
16. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer
17. Evaluation of an anticancer activity of a protein-bound polysaccharide PS-K (Krestin)
18. Experimental study on rational immunochemotherapy (in Japanese)
19. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil
20. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
21. Adjuvant immunochemotherapy in patients with gastric cancer (in Japanese)
22. Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin for patients with curatively resected gastric cancer-7 year survival-(in Japanese)
23. Multi-institutional cooperative study of adjuvant immunochemotherapy for gastric cancer: five year survival rate (in Japanese)